Valuation: Moderna, Inc.

Market Cap 69.62B 59.61B 55.61B 51.03B 95.89B 6,661B 97.78B 660B 257B 3,338B 261B 256B 11,052B P/E 2026 *
-20.3x
P/E 2027 * -35.9x
Enterprise Value 65.97B 56.48B 52.7B 48.36B 90.87B 6,312B 92.65B 625B 244B 3,163B 248B 242B 10,473B EV / Sales 2026 *
31.3x
EV / Sales 2027 * 27.4x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-25.91%
1 week+104.41%
Current month+137.34%
1 month+118.71%
3 months+170.39%
6 months+160.90%
Current year+341.20%
1 week 60.82
Extreme 60.82
176.66
1 month 52.66
Extreme 52.6601
176.66
Current year 29.81
Extreme 29.81
176.66
1 year 22.28
Extreme 22.28
176.66
3 years 22.28
Extreme 22.28
176.66
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

504,938 0.1273%
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-25.72%+104.41%+383.86%+17.13% 69.62B
-0.88%+3.53%+41.18%-1.18% 83.96B
+2.84%+23.66%-24.08%-36.73% 56.76B
+1.94%+1.61%-0.03%+32.78% 51.35B
+0.05%-0.55%+11.63%+167.36% 48.41B
-1.97%+3.45%+56.79%-17.79% 32.74B
-0.49%+6.38%+48.73%+97.60% 26.04B
+3.00%+5.91%+3.53%+221.78% 21.81B
-0.90%+2.85%+62.35%+124.85% 17.11B
-1.60%+2.20%+69.80%+190.21% 16.41B
Average -2.38%+21.84%+65.38%+79.60% 42.42B
Weighted average by Cap. -3.93%+33.38%+82.02%+49.15%

Financials

2026 *2027 *
Net sales 2.11B 1.8B 1.68B 1.54B 2.9B 202B 2.96B 19.96B 7.78B 101B 7.91B 7.74B 334B 2.46B 2.1B 1.96B 1.8B 3.38B 235B 3.45B 23.28B 9.08B 118B 9.22B 9.02B 390B
Net income -3.38B -2.89B -2.7B -2.48B -4.65B -323B -4.75B -32.02B -12.48B -162B -12.69B -12.41B -536B -1.9B -1.62B -1.51B -1.39B -2.61B -181B -2.66B -17.97B -7B -90.92B -7.12B -6.96B -301B
Net Debt -3.65B -3.12B -2.92B -2.67B -5.03B -349B -5.13B -34.58B -13.48B -175B -13.7B -13.4B -579B -2.29B -1.96B -1.83B -1.68B -3.15B -219B -3.21B -21.66B -8.44B -110B -8.58B -8.39B -363B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
20/08/26 US$132.52 -24.01% 74,674,241
19/08/26 US$174.38 +176.97% 199,252,328
18/08/26 US$62.96 -2.33% 4,304,996
17/08/26 US$64.46 +1.80% 3,979,550
14/08/26 US$63.32 -0.52% 4,700,891
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
174.38USD
Average target price
83.78USD
Spread / Average Target
-51.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock